256 related articles for article (PubMed ID: 21338705)
1. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
Alatrash G; de Lima M; Hamerschlak N; Pelosini M; Wang X; Xiao L; Kerbauy F; Chiattone A; Rondon G; Qazilbash MH; Giralt SA; de Padua Silva L; Hosing C; Kebriaei P; Zhang W; Nieto Y; Saliba RM; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1490-6. PubMed ID: 21338705
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
[TBL] [Abstract][Full Text] [Related]
3. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
[TBL] [Abstract][Full Text] [Related]
4. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
6. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q
J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705
[TBL] [Abstract][Full Text] [Related]
7. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
de Lima M; Couriel D; Thall PF; Wang X; Madden T; Jones R; Shpall EJ; Shahjahan M; Pierre B; Giralt S; Korbling M; Russell JA; Champlin RE; Andersson BS
Blood; 2004 Aug; 104(3):857-64. PubMed ID: 15073038
[TBL] [Abstract][Full Text] [Related]
8. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
10. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
11. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
12. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
Andersson BS; de Lima M; Thall PF; Wang X; Couriel D; Korbling M; Roberson S; Giralt S; Pierre B; Russell JA; Shpall EJ; Jones RB; Champlin RE
Biol Blood Marrow Transplant; 2008 Jun; 14(6):672-84. PubMed ID: 18489993
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Alatrash G; Thall PF; Valdez BC; Fox PS; Ning J; Garber HR; Janbey S; Worth LL; Popat U; Hosing C; Alousi AM; Kebriaei P; Shpall EJ; Jones RB; de Lima M; Rondon G; Chen J; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1792-1800. PubMed ID: 27377901
[TBL] [Abstract][Full Text] [Related]
14. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
[TBL] [Abstract][Full Text] [Related]
15. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
[TBL] [Abstract][Full Text] [Related]
16. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
17. Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
Uchida N; Matsumoto K; Sakura T; Hidaka M; Miyamoto T; Eto T; Maeda Y; Murayama T; Fujishima N; Yoshimoto G; Morita K; Kishimoto J; Teshima T; Taniguchi S; Yamashita T; Mori SI; Akashi K; Harada M;
Int J Hematol; 2020 Oct; 112(4):510-523. PubMed ID: 32656637
[TBL] [Abstract][Full Text] [Related]
18. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.
Andersson BS; Thall PF; Valdez BC; Milton DR; Al-Atrash G; Chen J; Gulbis A; Chu D; Martinez C; Parmar S; Popat U; Nieto Y; Kebriaei P; Alousi A; de Lima M; Rondon G; Meng QH; Myers A; Kawedia J; Worth LL; Fernandez-Vina M; Madden T; Shpall EJ; Jones RB; Champlin RE
Bone Marrow Transplant; 2017 Apr; 52(4):580-587. PubMed ID: 27991894
[TBL] [Abstract][Full Text] [Related]
20. Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
Chevallier P; Labopin M; de La Tour RP; Lioure B; Bulabois CE; Huynh A; Blaise D; Turlure P; Daguindau E; Maillard N; Yakoub-Agha I; Guillerm G; Delage J; Contentin N; Bay JO; Beckerich F; Bourhis JH; Detrait M; Vigouroux S; François S; Legrand F; Guillaume T; Mohty M;
Cancer Med; 2016 Nov; 5(11):3068-3076. PubMed ID: 27748046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]